The effects of comorbidity and age on RTOG study enrollment in stage iii non-small cell lung cancer patients who are eligible for RTOG studies

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 5, 2010, Pages 1394-1399

  Firat, Selim ^a   Byhardt, Roger W ^a   Gore, Elizabeth ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Age; Comorbidity; Lung cancer; Radiation therapy; RTOG

Indexed keywords

AGE; COMORBIDITY; LUNG CANCER; RADIATION THERAPY; RTOG;

BIOLOGICAL ORGANS; OPTICAL COMMUNICATION; RADIOTHERAPY;

EPIDEMIOLOGY;

AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; COMORBIDITY; CONSULTATION; DISEASE SEVERITY; GROUPS BY AGE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; WEIGHT REDUCTION;

AGE FACTORS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; COMORBIDITY; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; NEOPLASM STAGING; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; WEIGHT LOSS;

EID: 78549246163     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.09.051     Document Type: Article

References (32)

1. W.T. Sause, C. Scott, and S. Taylor Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: Preliminary results of a Phase III trial in regionally advanced, unresectable non-small-cell lung cancer J Natl Cancer Inst 87 1995 198 205
2. R.O. Dillman, S.L. Seagren, and K.J. Propert A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small-cell lung cancer N Engl J Med 323 1990 940 945
3. J.J.S. Ludbrook, P.T. Truong, and M.V. Macneil Do age and comorbidity impact treatment allocation and outcomes in limited stage small cell lung cancer? A community-based population analysis Int J Radiat Oncol Biol Phys 55 2003 1321 1330
4. E. Dajczman, L.Y. Fu, and D. Small Treatment of small cell lung carcinoma in the elderly Cancer 77 1996 2032 2038
5. C.J. Langer, J. Manola, and P. Bernardo Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial J Natl Cancer Inst 94 2002 173 181
6. C.M. Rocha Lima, J.E. Herndon, and M. Kosty Therapy choices among older patients with lung carcinoma Cancer 94 2002 181 187
7. T.R. Asmis, K. Ding, and L. Seymour Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group trials J Clin Oncol 26 2008 54 59
8. S.E. Schild, P.J. Stella, and S.M. Geyer The outcome of combined modality therapy for Stage III non-small-cell lung cancer in the elderly J Clin Oncol 21 2003 3201 3206
9. M.M. Kemeny, B.L. Peterson, and A.B. Kornblith Barriers to clinical trial participation by older women with breast cancer J Clin Oncol 21 2003 2268 2275
10. A.B. Kornblith, M. Kemeny, and B.L. Peterson Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials Cancer 95 2002 989 996
11. K.W. Yee, J.L. Pater, and L. Pho Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? J Clin Oncol 21 2003 1618 1623
12. L.F. Hutchins, J.M. Unger, and J.J. Crowley Underrepresentation of patients 65 years of age or older in cancer-treatment trials New Eng J Med 341 1999 2061 2067
13. E.L. Trimble, C.L. Carter, and D. Cain Representation of older patients in cancer treatment trials Cancer 74 1994 2014 2208
14. C. Gridelli, F. Perrone, and C. Gallo Chemotherapy for elderly patients with advanced non-small-cell lung cancer. Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial J Natl Cancer Inst 95 2003 362 372
15. G. Frasci, V. Lorusso, and N. Panza Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) Phase III trial Lung Cancer 34 Suppl 4 2001 s65 s69
16. M. Werner-Wasik, C. Scott, and J.D. Cox Recursive partitioning analysis of 1999 radiation therapy oncology group patients with locally-advanced non-small-cell lung cancer: Identification of five groups with different survival Int J Radiat Oncol Biol Phys 48 2000 1475 1482
17. B. Movsas, C. Scott, and W. Sause The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemo-radiation studies Int J Radiat Oncol Biol Phys 45 1999 1143 1149
18. C.J. Langer, C. Hsu, and W. Curran Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 94-10 Int J Radiat Oncol Biol Phys 2001 51; 3S1(Abstr.):31
19. M. Extermann, J. Overcash, and G.H. Lyman Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582 1587
20. E. Waldman, and J.F. Potter A prospective evaluation of the cumulative illness scale Aging 4 1992 171 178
21. M.D. Miller, C.F. Paradis, and P.R. Houck Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Scale Psychiatry Res 41 1992 237 248
22. B.S. Linn, M.W. Linn, and L. Gurel Cumulative Illness Rating Scale J Am Geriatr Soc 16 1968 622 626
23. M. Extermann Measuring comorbidity in older cancer patients Eur J Cancer 2000 453 471
24. M.D. Miller, and A. Towers A manual of guidelines for scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) 1991 University of Pittsburgh Pittsburgh, PA
25. A. Jatoi, S. Hillmann, and P. Stella Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group J Clin Oncol 23 2005 9113 9119
26. S. Firat, A. Pleister, and R.W. Byhardt Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of Stage III nonsmall cell lung cancer (NSCLC) Am J Clin Oncol 29 2006 252 257
27. S. Firat, M. Bousamra, and E. Gore Comorbidity and KPS are independent prognostic factors in Stage I non-small cell lung cancer Int J Radiat Biol Phys 52 2002 1047 1057
28. H.I. Hall, W.A. Satariano, and T. Thompson Initial treatment for prostate carcinoma in relation to comorbidity and symptoms Cancer 95 2002 2308 2315
29. S. Greenfield, D.M. Blanco, and R.M. Elashoff Patterns of care related to age of breast cancer patients JAMA 257 1987 2766 2770
30. J.M. de Rijke, L.J. Schouten, and G.P. ten Velde Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study Lung Cancer 46 2004 233 245
31. N.L. Keating, M.B. Landrum, and C.N. Klabunde Adjuvant chemotherapy for Stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26 2008 2532 2537
32. S. Firat, R.W. Byhardt, and E. Gore Comorbidity and Karnofsky Performance Score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies Int J Radiat Biol Phys 54 2002 357 364